Empresas›VRXA

VRXA · Veraxa Biotech Holding AG

preparados farmaceuticos · CIK 0002079109

Veraxa Biotech Holding AG (VRXA) cotiza en el NASDAQ y se dedica a preparados farmaceuticos. Aqui estan 11 documentos que ha presentado ante la SEC, desde 27 jul 2026. En sus informes aparecen frases que este sitio vigila: duda sustancial sobre la continuidad de la empresa y debilidad material en el control interno. Estan citadas literalmente mas abajo.

Documentos

11

recogidos hasta hoy

Ultimo

10 ago 2026

Nueva emision de acciones con precio

Todavia no se publican los trimestres de caja ni la dilucion de esta empresa: hacen falta datos de sus informes que solo se recogen de las que se siguen de cerca. Lo que ves abajo son sus documentos tal y como los presento ante la SEC.

Documentos presentados ante la SEC

2026

1. 10 ago 2026424B5Nueva emision de acciones con precioEDGAR

   Veraxa afirma que puede financiar sus operaciones planificadas y cumplir sus obligaciones durante al menos los proximos doce meses, y que no existe duda sustancial sobre su capacidad para continuar como negocio en marcha.

   Lo que dice el documentoto fund its planned operations and meet its obligations as they become due for at least the twelve months from the date these consolidated financial statements are available to be issued, and that no substantial doubt exists about the Company’s ability to continue as a going concern.

   Traduccion automatica (claude-sonnet-5), verificada contra el texto original.

   Veraxa ha identificado una debilidad material en sus controles internos sobre la informacion financiera.

   Lo que dice el documentoWe have identified a material weakness in our internal controls over financial reporting. Failure to establish and maintain effective internal controls in accordance with Section404 of the Sarbanes-Oxley Act in the future could have a material adverse effect on our business and stock price.

   Traduccion automatica (claude-sonnet-5), verificada contra el texto original.

   Duda sustancial sobre la continuidad de la empresa…to fund its planned operations and meet its obligations as they become due for at least the twelve months from the date these consolidated financial statements are available to be issued, and that no substantial doubt exists about the Company’s ability to continue as a going concern. Cash flows for the years ended December31, 2025 and 2024 The following table summarizes Veraxa’s cash flows from operating, investing and financing activities for the years ended December 31, 2025 and…

   Debilidad material en el control interno…necessitated by ongoing revisions to disclosure and governance practices, which could have a material adverse impact on our business, financial condition, results of operations and prospects. We have identified a material weakness in our internal controls over financial reporting. Failure to establish and maintain effective internal controls in accordance with Section404 of the Sarbanes-Oxley Act in the future could have a material…

2. 10 ago 2026424B5Nueva emision de acciones con precioEDGAR
   Duda sustancial sobre la continuidad de la empresaver la frase en el documento (ingles)

   …to fund its planned operations and meet its obligations as they become due for at least the twelve months from the date these consolidated financial statements are available to be issued, and that no substantial doubt exists about the Company’s ability to continue as a going concern. Cash flows for the years ended December31, 2025 and 2024 The following table summarizes Veraxa’s cash flows from operating, investing and financing activities for the years ended December 31, 2025 and…

   Debilidad material en el control internover la frase en el documento (ingles)

   …necessitated by ongoing revisions to disclosure and governance practices, which could have a material adverse impact on our business, financial condition, results of operations and prospects. We have identified a material weakness in our internal controls over financial reporting. Failure to establish and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act in the future could have a material…
3. 6 ago 2026EFFECTRegistro declarado efectivoEDGAR
4. 6 ago 2026EFFECTRegistro declarado efectivoEDGAR
5. 5 ago 2026F-1/ASalida a bolsa (emisor extranjero, enmienda)EDGAR
6. 5 ago 2026F-1/ASalida a bolsa (emisor extranjero, enmienda)EDGAR
7. 31 jul 20266-KHecho relevante (emisor extranjero)EDGAR
8. 31 jul 2026F-1Salida a bolsa (emisor extranjero)EDGAR
9. 31 jul 2026F-1Salida a bolsa (emisor extranjero)EDGAR
10. 27 jul 20266-KHecho relevante (emisor extranjero)EDGAR
11. 27 jul 20266-KHecho relevante (emisor extranjero)EDGAR